HoUng Kim

1.4k citations
8 papers · 1.0k indexed · 1 hit paper · h-index 8

Impact in

  • Immunology top 5%
    • Biosimilars and Bioanalytical Methods
    • Rheumatoid Arthritis Research and Therapies

Papers in

HoUng Kim

8 papers receiving 984 citations

Hit Papers

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study 2013 · 487 citations
4872013202620172021100200300400

Peers

HoUng Kim
Comparison fields: 5 of 45
  • Immunology 893
  • Rheumatology 284
  • Pediatrics, Perinatology and Child Health 319
  • Economics and Econometrics 326
  • Genetics 204
Replace Volodymyr Kovalenko with:
Volodymyr Kovalenko Ukraine
Edgar Ramiterre United States
Helēna Mikažāne Latvia
S. Shevchuk Ukraine
Mariusz Piotrowski Poland
Roman Yatsyshyn Ukraine
Sadiq Lula United States
W. Porawska Poland
P.P.M. van Lümig Netherlands
Joyce Ford United States
HoUng Kim relative to Volodymyr Kovalenko Ukraine Volodymyr Kovalenko's profile →
Citations per field
00.5×1.5×
Volodymyr Kovalenko · 1×
Citations per year

Countries citing papers authored by HoUng Kim

Since Specialization
Citations

This map shows the geographic impact of HoUng Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by HoUng Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites HoUng Kim more than expected).

Fields of papers citing papers by HoUng Kim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by HoUng Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by HoUng Kim. The network helps show where HoUng Kim may publish in the future.

Co-authors

The 25 scholars most cited alongside HoUng Kim, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with HoUng Kim Line = papers co-authored together HoUng Kim links everyone, so they are left out of the graph.

All Works

8 of 8 papers shown
#Work
1 202122
2 202073
3 20187
4 201810
5 2016203
6 2016170
7 201535
8
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
Hit paper breakdown →
2013487

About HoUng Kim

HoUng Kim is a scholar working on Immunology, Pediatrics, Perinatology and Child Health, Rheumatology, Radiology, Nuclear Medicine and Imaging and Oncology, having authored 8 papers that have together received 1.0k indexed citations. Recurring topics across this work include Biosimilars and Bioanalytical Methods (6 papers), Pharmaceutical studies and practices (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Rheumatoid Arthritis Research and Therapies (3 papers), HER2/EGFR in Cancer Research (2 papers), Microscopic Colitis (2 papers), Pharmaceutical Economics and Policy (1 paper) and Spondyloarthritis Studies and Treatments (1 paper). The work is most often cited by research in Immunology (893 citations), Rheumatology (284 citations), Pediatrics, Perinatology and Child Health (319 citations), Economics and Econometrics (326 citations) and Genetics (204 citations). HoUng Kim has collaborated with scholars based in South Korea, United Kingdom and Germany. Frequent co-authors include Pedro C. Miranda, Dae‐Hyun Yoo, Won Park, Nenad Prodanović, Edgar Ramiterre, Sang Joon Lee, Sergio Gutiérrez‐Ureña, S. Shevchuk, Mauricio Abello-Banfi and Ulf Müller‐Ladner. Their work appears in journals such as Annals of the Rheumatic Diseases, Drugs, Cancer Chemotherapy and Pharmacology, mAbs and Future Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026